Biotech Values

[mcbio]

Interim-data table from GILD’s phase-2 LONESTAR study

One important question to keep in mind is how likely is that very good 8-week treatment duration with SVR8 number of 95% in the sofosbuvir+ledipasvir arm or the 100% SVR8 with addition of ribavirin likely to translate into SVR12 and beyond? I ask in connection with the prior ABBV data that showed relapse later on despite the initial very promising earlier SVR data. While this data is indeed very promising, we certainly need to see further data.